CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction-A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat.

Roof, Steve R; Ueyama, Yukie; Mazhari, Reza; Hamlin, Robert L; Hartman, J Craig; Ziolo, Mark T; Reardon, John E; Del Rio, Carlos L

Roof, Steve R; Ueyama, Yukie; Mazhari, Reza; Hamlin, Robert L; Hartman, J Craig; Ziolo, Mark T; Reardon, John E; Del Rio, Carlos L.

Afiliación

Roof SR; QTest Labs, Columbus, OH, United States.
Ueyama Y; QTest Labs, Columbus, OH, United States.
Mazhari R; Cardioxyl Pharmaceuticals, Chapel Hill, NC, United States.
Hamlin RL; QTest Labs, Columbus, OH, United States.
Hartman JC; Cardioxyl Pharmaceuticals, Chapel Hill, NC, United States.
Ziolo MT; Ohio State University Columbus, Columbus, OH, United States.
Reardon JE; Cardioxyl Pharmaceuticals, Chapel Hill, NC, United States.
Del Rio CL; QTest Labs, Columbus, OH, United States.

Front Physiol ; 8: 894, 2017.

Article en En | MEDLINE | ID: mdl-29209225

Palabras clave

CXL-1020; cardiac diastolic dysfunction; cardiovascular therapeutic; nitroxyl

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Physiol Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google